ArticleFrontiers in immunology2026
NAMPT orchestrates fibroblast cuproptosis and immune crosstalk during IPF progression.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by excessive fibroblast activation and extracellular matrix deposition, leading to severe tissue remodeling and poor prognosis. While current treatments offer limited efficacy. Emerging evidence suggests cuproptosis, a novel form of copper-dependent cell death, as a potential mechanism influencing fibroblast survival and fibrogenesis. Methods: Bulk RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics were utilized to analyze gene expression profiles from IPF patient samples and healthy controls. Differentially expressed genes related to copper regulation and cell death pathways were identified using machine learning algorithms. Immune infiltration was assessed using CIBERSORT, and cell-cell interactions were explored using the CellChat algorithm. Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) were employed to explore the role of nicotinamide phosphoribosyltransferase (NAMPT) in cuproptosis and fibrosis-related pathways. Results: Transcriptomic analysis identified NAMPT as a key hub gene in IPF, with strong positive correlation to cuproptosis. Spatial transcriptomics revealed elevated cuproptosis activity in NAMPT+ fibroblasts localized in fibrotic lesions. Additionally, NAMPT+ fibroblasts exhibited increased crosstalk with M2 macrophages through the C3-ITGB2 complement pathway, implicating NAMPT in promoting fibroblast activation and shaping a pro-fibrotic immune microenvironment. Conclusion: This study identifies NAMPT as a critical regulator of cuproptosis in IPF fibroblasts and highlights its dual role in fibroblast activation and immune modulation. Targeting NAMPT offers a promising therapeutic strategy for modulating fibroblast behavior, reducing fibrosis, and disrupting the pro-fibrotic cell communication network in IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.